TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15252213

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA) at 2.0 mg/kg up to 80 mg
Number of subjects: 37

Group type: COMPARATOR
Intervention: Triamcinolone hexacetonide (TH) at 1 mg/kg up to 40 mg
Number of subjects: 37

Group type: COMPARATOR
Intervention: Triamcinolone hexacetonide (TH)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA)
Number of subjects: 37
Study: 11682374

Group type: COMPARATOR
Intervention: Routine medical information through an informative pamphlet (Group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Extensive oral medical information and more personal attention by the surgeon (Group II)
Number of subjects: 60
Study: 9782138

Group type: EXPERIMENTAL
Intervention: Goserelin depot treatment for 8 weeks before endometrial resection
Number of subjects: 63

Group type: COMPARATOR
Intervention: Immediate surgery in the early proliferative phase of the cycle
Number of subjects: 63
Study: 8145906

Group type: EXPERIMENTAL
Intervention: rIFNA (9 million IU, intramuscularly every other day for 6 months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (intramuscularly every other day for 6 months)
Number of subjects: 20
Study: 3136830

Group type: EXPERIMENTAL
Intervention: Buserelin and human menopausal gonadotrophin
Number of subjects: 405

Group type: COMPARATOR
Intervention: Clomiphene citrate and human menopausal gonadotrophin
Number of subjects: 405
Study: 31175711

Group type: EXPERIMENTAL
Intervention: Perindopril + Amlodipine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Perindopril + Indapamide
Number of subjects: 30
Study: 27705012

Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation (PCS)
Number of subjects: 956

Group type: COMPARATOR
Intervention: Anesthesiologist administered propofol sedation
Number of subjects: 956

Group type: COMPARATOR
Intervention: All methods of sedation
Number of subjects: 956
Study: 26246593

Group type: EXPERIMENTAL
Intervention: Parent Education Through Simulation‐Diabetes (PETS‐D)
Number of subjects: 191
Study: 24059875

Group type: EXPERIMENTAL
Intervention: A‐SEMI (community-based intervention)
Number of subjects: 278

Group type: COMPARATOR
Intervention: HPC (health promotion condition)
Number of subjects: 278
Study: 22103045

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg bid, Clarithromycin 500 mg bid, Amoxycillin 1gr bid for 7 days
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg bid, Clarithromycin 500 mg bid, Amoxycillin 1gr bid for 10 days
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg bid, Clarithromycin 500 mg bid, Amoxycillin 1gr bid for 14 days
Number of subjects: 307
Study: 19696643

Group type: EXPERIMENTAL
Intervention: Tri-iodothyronine (T3)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both T3 and MP
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 16510816

Group type: COMPARATOR
Intervention: Open reduction and screw fixation
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Primary arthrodesis of the medial two or three rays
Number of subjects: 41
Study: 12771984

Group type: EXPERIMENTAL
Intervention: Lifetime cumulative tobacco consumption and alcohol consumption
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Clear eyes
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Cumulative sun exposure during outdoor work
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Skin reaction to sun exposure (Fitzpatrick levels)
Number of subjects: 105
Study: 10696955

Group type: EXPERIMENTAL
Intervention: Iron supplementation (66 mg iron tablets)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 206
Study: 9491846

Group type: EXPERIMENTAL
Intervention: Etoposide: 200 mg x day x 5 days orally every 3 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fluorouracil: 500 mg x m2, Doxorubicin: 50 mg/m2, Cyclophosphamide: 500 mg/m2 intravenously every 3 weeks
Number of subjects: 60
Study: 11767315

Group type: EXPERIMENTAL
Intervention: Ringer's lactate (2 litres over half an hour)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Gelatin (0.8 litre over half an hour)
Number of subjects: 8
Study: 3735050

Group type: EXPERIMENTAL
Intervention: New Generation cup
Number of subjects: 123

Group type: COMPARATOR
Intervention: BIRD's original vacuum extractor cup
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 123
Study: 28256100

Group type: EXPERIMENTAL
Intervention: UWIN questionnaire
Number of subjects: 294

Group type: COMPARATOR
Intervention: AUASI questionnaire
Number of subjects: 294
Study: 28390206

Group type: EXPERIMENTAL
Intervention: Test Toothbrush (soft toothbrush with tapered-tip bristles)
Number of subjects: 71

Group type: COMPARATOR
Intervention: ADA Toothbrush (ADA reference toothbrush)
Number of subjects: 71
Study: 24468678

Group type: EXPERIMENTAL
Intervention: Phaseolin treated mice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 22490179

Group type: EXPERIMENTAL
Intervention: Active musical experience for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive exposure to music for 6 months
Number of subjects: 0
Study: 20362709

Group type: EXPERIMENTAL
Intervention: NT‐proBNP guided care
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard HF management
Number of subjects: 151
Study: 19025304

Group type: EXPERIMENTAL
Intervention: Hp-seropositive university students' families
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hp-seronegative university students' families
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Families of Hp-positive students
Number of subjects: 30

Group type: COMPARATOR
Intervention: Families of Hp-negative students
Number of subjects: 30
Study: 16020262

Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate ophthalmic gelling vehicle
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.5% timolol maleate ophthalmic solution
Number of subjects: 0
Study: 12823166

Group type: EXPERIMENTAL
Intervention: NET + WT
Number of subjects: 102

Group type: COMPARATOR
Intervention: WT alone
Number of subjects: 102
Study: 11284610

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 60
Study: 8646871

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate cream, 0.05%
Number of subjects: 120

Group type: COMPARATOR
Intervention: Hydrocortisone-17-butyrate cream, 0.1%
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 120
Study: 8134276

Group type: EXPERIMENTAL
Intervention: CAD CAM (CAPOD) socket
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional socket
Number of subjects: 22
Study: 3302925

Group type: EXPERIMENTAL
Intervention: Rimantadine for five days
Number of subjects: 91

Group type: COMPARATOR
Intervention: Acetaminophen for five days
Number of subjects: 91
Study: 29553289

Group type: EXPERIMENTAL
Intervention: Endurance and resistance training (training group, TG)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 27
Study: 27583312

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 374

Group type: COMPARATOR
Intervention: Enoxaparin/Warfarin
Number of subjects: 374
Study: 26577962

Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT) using Vacuum Assisted Closure (VAC)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Advanced Moist Wound Therapy (AMWT)
Number of subjects: 278
Study: 23890516

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin (10/20 and 10/40 mg)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: atorvastatin (10, 20, 40 mg)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin
Number of subjects: 1000

Group type: COMPARATOR
Intervention: atorvastatin
Number of subjects: 1000
Study: 21909448

Group type: EXPERIMENTAL
Intervention: DENV-1 infection
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Secondary dengue infection
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Secondary infection
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Primary vs Secondary infections
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: DHF
Number of subjects: 248
Study: 18184117

Group type: EXPERIMENTAL
Intervention: AZD0865 (25, 50, or 75 mg/day)
Number of subjects: 1469

Group type: COMPARATOR
Intervention: Esomeprazole 20 mg/day
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: AZD0865 75 mg/day
Number of subjects: 1469

Group type: COMPARATOR
Intervention: Esomeprazole 20 mg
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: AZD0865 (all doses)
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: AZD0865
Number of subjects: 1469
Study: 17009840

Group type: COMPARATOR
Intervention: Reference formulation (250 mg, 10 ml)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Test formulation (Pactens) (250 mg, 10 ml)
Number of subjects: 24
Study: 14648727

Group type: EXPERIMENTAL
Intervention: Multimodal optimization
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 25
Study: 11082378

Group type: EXPERIMENTAL
Intervention: Fontan patients (TCPC)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Fontan patients (APC)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Normal healthy volunteers (control)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 68
Study: 8907209

Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet plus cholestyramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet and cholestyramine
Number of subjects: 0
Study: 10303913

Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study: 619945

Group type: EXPERIMENTAL
Intervention: Oral propranolol (80 mg) with metoclopramide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral propranolol (80 mg) with normal saline
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral propranolol (80 mg) with propantheline
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oral propranolol (80 mg)
Number of subjects: 10
Study: 31433921

Group type: EXPERIMENTAL
Intervention: CABG plus medical therapy
Number of subjects: 601

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Both treatment groups (CABG and medical therapy, medical therapy alone)
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Patients with myocardial viability
Number of subjects: 601
Study: 28167190

Group type: EXPERIMENTAL
Intervention: Pectoralis minor muscle stretching by active scapular retraction
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (upright position)
Number of subjects: 60
Study: 25978741

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 800

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study: 23053133

Group type: EXPERIMENTAL
Intervention: Creatine (CR, N = 9)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (PL, N = 9)
Number of subjects: 18
Study: 22074851

Group type: EXPERIMENTAL
Intervention: Multi-condition collaborative care intervention for depression and poorly controlled diabetes and/or risk factors for coronary heart disease over 12 months.
Number of subjects: 214

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Multi-condition collaborative care intervention for disabilities in activities of daily living.
Number of subjects: 214
Study: 19365567

Group type: EXPERIMENTAL
Intervention: RTS,S/AS02A vaccine
Number of subjects: 2022

Group type: COMPARATOR
Intervention: Control vaccines
Number of subjects: 2022
Study: 16436363

Group type: EXPERIMENTAL
Intervention: Practice of S1 followed by S2 (experimental group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Practice of S1 only (control group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Practice of S2 after S1 (experimental group)
Number of subjects: 30
Study: 15574629

Group type: EXPERIMENTAL
Intervention: Hydrocortisone, 1 mg/kg per day for 12 days, then 0.5 mg/kg per day for 3 days
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Hydrocortisone with indomethacin
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo with indomethacin
Number of subjects: 360
Study: 11382656

Group type: EXPERIMENTAL
Intervention: Iron-fortified candies (30 g/week for 12 weeks, containing 1 mg elemental Fe/g)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo candies (30 g/week for 12 weeks)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Iron-fortified candies
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo candies
Number of subjects: 117
Study: 9458496

Group type: EXPERIMENTAL
Intervention: Combined reporting of increased serum calcium and results from diagnostic discriminating calculations in group A
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard reporting of serum calcium only if requested in group B
Number of subjects: 87
Study: 7924775

Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD) - 0.5 g.kg‐1.day‐1 of proteins, 7% calories as protein, 33% as fat, and 60% as carbohydrates
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Normoproteic isocaloric test diet (chicken and fish)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Usual diet (UD)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Usual diet (UD) in hyperfiltering group
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD) in hyperfiltering group
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Normoproteic isocaloric test diet (chicken and fish) in hyperfiltering group
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: All diets (LPD and test diet)
Number of subjects: 15
Study: 2894166

Group type: EXPERIMENTAL
Intervention: rilmenidine (1 mg once daily, doubled to 1 mg twice daily if BP > 90 mm Hg)
Number of subjects: 58

Group type: COMPARATOR
Intervention: methyldopa (250 mg twice daily, doubled to 500 mg twice daily if BP > 90 mm Hg)
Number of subjects: 58
Study: 31283717

Group type: EXPERIMENTAL
Intervention: High adherence to home-based rehabilitation
Number of subjects: 88

Group type: COMPARATOR
Intervention: Low adherence to home-based rehabilitation
Number of subjects: 88
Study: 28202896

Group type: EXPERIMENTAL
Intervention: Hypercapnia (ETCO2 45 mmHg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normocapnia (ETCO2 35 mmHg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (Hypercapnia and Normocapnia)
Number of subjects: 40
Study: 25400252

Group type: EXPERIMENTAL
Intervention: Allopurinol treatment
Number of subjects: 176

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 176
Study: 23103798

Group type: EXPERIMENTAL
Intervention: Posterior tibial nerve stimulation (weekly session for 12 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Posterior tibial nerve stimulation (3-month follow-up)
Number of subjects: 28
Study: 20825792

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Promethazine 12.5 mg
Number of subjects: 163

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 163
Study: 18713548

Group type: EXPERIMENTAL
Intervention: Salmon calcitonin 50 U three times a week for 12 months
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Salmon calcitonin 100 U three times a week for 12 months
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (oral calcium carbonate 1500 mg tid and rocaltrol 0.25 microg qn for 12 months)
Number of subjects: 148
Study: 17065354

Group type: EXPERIMENTAL
Intervention: Glucosamine (500 mg p.o. t.i.d. for 6 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 14685952

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 8 weeks
Number of subjects: 61
Study: 10910888

Group type: EXPERIMENTAL
Intervention: CD4zeta-modified CD4(+) and CD8(+) T cells with IL-2 (n = 11)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CD4zeta-modified CD4(+) and CD8(+) T cells without IL-2 (n = 13)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CD4zeta-modified T cells (both groups)
Number of subjects: 24
Study: 10172622

Group type: EXPERIMENTAL
Intervention: Day treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 0
Study: 1568692

Group type: EXPERIMENTAL
Intervention: 60 mg slow-release nifedipine (Aprical long 60 mg) administered daily at 1800 hours
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 6206207

Group type: EXPERIMENTAL
Intervention: ACOMLA (doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine)
Number of subjects: 48

Group type: COMPARATOR
Intervention: CHOP-B (cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combined treatment groups (ACOMLA and CHOP-B)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Follicular center-cell origin lymphoma
Number of subjects: 48
Study: 31286903

Group type: EXPERIMENTAL
Intervention: Schroth exercise intervention added to standard care (daily home exercises and weekly therapy sessions)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard care alone (Control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Schroth exercise intervention
Number of subjects: 50
Study: 30059843

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg every 2 weeks (Q2W)
Number of subjects: 812

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 812
Study: 27635481

Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study: 24044912

Group type: EXPERIMENTAL
Intervention: SWL with simultaneous inversion therapy (30 head down Trendelenburg position)
Number of subjects: 140

Group type: COMPARATOR
Intervention: SWL with hydration alone
Number of subjects: 140
Study: 21751891

Group type: EXPERIMENTAL
Intervention: Ozone-oxygen treatment
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (sham treatment)
Number of subjects: 61
Study: 19261730

Group type: EXPERIMENTAL
Intervention: 4.4 g/d ALA for 6 weeks
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 2.2 g/d EPA for 6 weeks
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 2.3 g/d DHA for 6 weeks
Number of subjects: 74
Study: 17132119

Group type: EXPERIMENTAL
Intervention: Nightly stretch intervention (splinted into a stretched, abducted position each night for 12 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (not splinted)
Number of subjects: 44
Study: 15585769

Group type: EXPERIMENTAL
Intervention: Cow milk
Number of subjects: 31

Group type: COMPARATOR
Intervention: Nonmilk
Number of subjects: 31
Study: 11389292

Group type: EXPERIMENTAL
Intervention: Breast pumping using a double electric breast pump for six 10‐ to 15‐minute sessions from 24 to 72 hours postpartum
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group held the pump to their breasts without suction for the same amount of time
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Breast pumping
Number of subjects: 60
Study: 9129472

Group type: EXPERIMENTAL
Intervention: Parboiled rice-PUFA meal
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dietary PUFA
Number of subjects: 8
Study: 8101096

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg three times daily and 800 mg in the evening on the day preceding ebastine administration and 400 mg four times daily on the 2 following days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3102217

Group type: EXPERIMENTAL
Intervention: Inhalation of monodisperse Teflon particles labelled with 111In, 8.2 micron aerodynamic diameter
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Inhalation of monodisperse Teflon particles labelled with 111In, 11.5 micron aerodynamic diameter
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Inhalation of monodisperse Teflon particles labelled with 111In, 13.7 micron aerodynamic diameter
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Inhalation of monodisperse Teflon particles labelled with 111In, 16.4 micron aerodynamic diameter
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alveolar deposition for 8.2 micron particles
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alveolar deposition for 11.5 micron particles
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alveolar deposition for 13.7 micron particles
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alveolar deposition for 16.4 micron particles
Number of subjects: 24
Study: 797216

Group type: EXPERIMENTAL
Intervention: 200 mg doxantrazole
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 400 mg doxantrazole
Number of subjects: 10

Group type: COMPARATOR
Intervention: 400 mg doxantrazole three times a day for 14 days
Number of subjects: 10
Study: 31548680

Group type: EXPERIMENTAL
Intervention: Hybrid batterer intervention programme (BIP) plus circles of peace (CP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Typical batterer intervention programme (BIP)
Number of subjects: 0
Study: 28074677

Group type: EXPERIMENTAL
Intervention: Tamsulosin, Solifenacin, and Trospium
Number of subjects: 452
Study: 26033126

Group type: EXPERIMENTAL
Intervention: Direct ARDS
Number of subjects: 953

Group type: EXPERIMENTAL
Intervention: Direct ARDS (multicenter study)
Number of subjects: 953

Group type: COMPARATOR
Intervention: Indirect ARDS
Number of subjects: 953
Study: 23910889

Group type: EXPERIMENTAL
Intervention: QRS-loop parameters (maximum vector magnitude, planar area, maximum distance between centroid and loop, perimeter) combined with STC(VM), QRS(VD), and SVG indexes
Number of subjects: 51
Study: 21288326

Group type: EXPERIMENTAL
Intervention: Combination of 2 drugs added to standard treatment
Number of subjects: 750

Group type: COMPARATOR
Intervention: Factorial design with one‐ to sixteen‐fold the sample size of the combination trial
Number of subjects: 750

Group type: COMPARATOR
Intervention: Factorial design with lower sample size
Number of subjects: 750

Group type: COMPARATOR
Intervention: Adequately powered 2 x 2 factorial design
Number of subjects: 750